The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Research Report 2024
Synopsis
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment of Chemotherapy-Induced Nausea in Cancer Patients market research.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment of Chemotherapy-Induced Nausea in Cancer Patients report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.
Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market is projected to reach US$ 2123.1 million in 2029, increasing from US$ 2368.6 million in 2022, with the CAGR of -1.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Treatment of Chemotherapy-Induced Nausea in Cancer Patients market research.
The chemotherapy-induced nausea and vomiting (CINV) treatment market is driven by the increasing prevalence of cancer and the growing adoption of effective antiemetic therapies. Chemotherapy often causes nausea and vomiting, adversely affecting the quality of life of cancer patients. The rise in cancer incidence and the need for better supportive care contribute to market growth as healthcare providers and patients seek reliable CINV treatments to manage these distressing side effects. Moreover, advancements in antiemetic drug development and the introduction of combination therapies have improved treatment efficacy and patient outcomes. However, the market also faces challenges, including the individual variability in CINV response and the need for tailored treatment approaches. Additionally, addressing the cost of antiemetic drugs and ensuring accessibility to patients can pose obstacles for widespread adoption. To succeed, companies must focus on research and development to offer innovative and patient-centric CINV treatments, collaborate with oncologists to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated antiemetic therapies for cancer patients undergoing chemotherapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Treatment of Chemotherapy-Induced Nausea in Cancer Patients market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Treatment of Chemotherapy-Induced Nausea in Cancer Patients report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 5-HT3 Inhibitors
1.2.3 NK1 Inhibitors
1.2.4 Other
1.3 Market by Application
1.3.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute CINV
1.3.3 Delayed CINV
1.3.4 Breakthrough CINV
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Perspective (2018-2029)
2.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Growth Trends by Region
2.2.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Historic Market Size by Region (2018-2023)
2.2.3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecasted Market Size by Region (2024-2029)
2.3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Dynamics
2.3.1 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Industry Trends
2.3.2 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Drivers
2.3.3 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Challenges
2.3.4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treatment of Chemotherapy-Induced Nausea in Cancer Patients Players by Revenue
3.1.1 Global Top Treatment of Chemotherapy-Induced Nausea in Cancer Patients Players by Revenue (2018-2023)
3.1.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue Market Share by Players (2018-2023)
3.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue
3.4 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Concentration Ratio
3.4.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treatment of Chemotherapy-Induced Nausea in Cancer Patients Revenue in 2022
3.5 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Key Players Head office and Area Served
3.6 Key Players Treatment of Chemotherapy-Induced Nausea in Cancer Patients Product Solution and Service
3.7 Date of Enter into Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Breakdown Data by Type
4.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Historic Market Size by Type (2018-2023)
4.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecasted Market Size by Type (2024-2029)
5 Treatment of Chemotherapy-Induced Nausea in Cancer Patients Breakdown Data by Application
5.1 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Historic Market Size by Application (2018-2023)
5.2 Global Treatment of Chemotherapy-Induced Nausea in Cancer Patients Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size (2018-2029)
6.2 North America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2018-2023)
6.4 North America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size (2018-2029)
7.2 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2018-2023)
7.4 Europe Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size (2018-2029)
8.2 Asia-Pacific Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2018-2023)
8.4 Asia-Pacific Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size (2018-2029)
9.2 Latin America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2018-2023)
9.4 Latin America Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size (2018-2029)
10.2 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2018-2023)
10.4 Middle East & Africa Treatment of Chemotherapy-Induced Nausea in Cancer Patients Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Heron Therapeutics
11.1.1 Heron Therapeutics Company Detail
11.1.2 Heron Therapeutics Business Overview
11.1.3 Heron Therapeutics Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.1.4 Heron Therapeutics Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.1.5 Heron Therapeutics Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.2.4 Merck Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.2.5 Merck Recent Development
11.3 Eisai
11.3.1 Eisai Company Detail
11.3.2 Eisai Business Overview
11.3.3 Eisai Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.3.4 Eisai Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.3.5 Eisai Recent Development
11.4 Mundipharma
11.4.1 Mundipharma Company Detail
11.4.2 Mundipharma Business Overview
11.4.3 Mundipharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.4.4 Mundipharma Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.4.5 Mundipharma Recent Development
11.5 Qilu Pharma
11.5.1 Qilu Pharma Company Detail
11.5.2 Qilu Pharma Business Overview
11.5.3 Qilu Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.5.4 Qilu Pharma Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.5.5 Qilu Pharma Recent Development
11.6 Teva
11.6.1 Teva Company Detail
11.6.2 Teva Business Overview
11.6.3 Teva Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.6.4 Teva Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.6.5 Teva Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.7.4 Novartis Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Roche
11.8.1 Roche Company Detail
11.8.2 Roche Business Overview
11.8.3 Roche Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.8.4 Roche Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.8.5 Roche Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.9.4 Mylan Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.9.5 Mylan Recent Development
11.10 Baxter
11.10.1 Baxter Company Detail
11.10.2 Baxter Business Overview
11.10.3 Baxter Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.10.4 Baxter Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.10.5 Baxter Recent Development
11.11 GSK
11.11.1 GSK Company Detail
11.11.2 GSK Business Overview
11.11.3 GSK Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.11.4 GSK Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.11.5 GSK Recent Development
11.12 Helsinn
11.12.1 Helsinn Company Detail
11.12.2 Helsinn Business Overview
11.12.3 Helsinn Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.12.4 Helsinn Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.12.5 Helsinn Recent Development
11.13 Southwest Pharma
11.13.1 Southwest Pharma Company Detail
11.13.2 Southwest Pharma Business Overview
11.13.3 Southwest Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.13.4 Southwest Pharma Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.13.5 Southwest Pharma Recent Development
11.14 Haisco
11.14.1 Haisco Company Detail
11.14.2 Haisco Business Overview
11.14.3 Haisco Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.14.4 Haisco Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.14.5 Haisco Recent Development
11.15 Sun Pharma
11.15.1 Sun Pharma Company Detail
11.15.2 Sun Pharma Business Overview
11.15.3 Sun Pharma Treatment of Chemotherapy-Induced Nausea in Cancer Patients Introduction
11.15.4 Sun Pharma Revenue in Treatment of Chemotherapy-Induced Nausea in Cancer Patients Business (2018-2023)
11.15.5 Sun Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
